表观沉默蛋白SUZ12与胃癌病理特征及预后的关系

The relationship between suppressor of zeste 12 expression and clinical features of gastric cancer

目的探讨表观沉默蛋白SUZ12在胃癌组织中的表达及其与胃癌患者临床病理指标和预后的关系。方法采用免疫组化染色方法检测SUZ12蛋白在97例胃癌组织中的表达，分析其与胃癌患者临床病理学指标及生存的关系。结果SUZ12蛋白在本组胃癌组织中的阳性率为43％，明显高于临近非癌组织的15％（P=0．002）。SUZ12基因表达与胃癌的分化程度（P=0．018）、淋巴结转移（P=0．023）、TNM分期密切相关（P=0．014）。SUZ12表达阳性患者的预后明显比阴性患者差（P=0．024），为独立预后因素。结论SUZ12基因可能在胃癌发生发展中起促进作用，其过表达程度可以作为胃癌某些生物学行为及判断预后的新的参考指标。

Objective To investigate the relationship between the expression of suppressor of zeste 12 （SUZ12） and the clinicopathological parameters and prognosis in patients with gastric cancer. Methods SUZ12 protein expression levels in 97 cases of resected gastric cancer were detected by immunohitochemistry method, the relations between SUZ12 expression levels and the survival were estimated by Kaplan-Meier curve. Results The positive rate of SUZ12 expression in gastric cancer tissues was 43%, significantly higher than that （15%）in the adjacent noncancerous tissues （P = 0. 002）. SUZ12-positive expression was significantly correlated with tumor differentiation （ P = 0. 018 ）, lymph nodes metastasis （ P = 0. 023 ） and TNM staging（P = 0. 014）. Gastric cancer patients with SUZ12-positive expression had worse prognosis than those with SUZ12-negative expression （ P = 0. 024 ）. Conclusions SUZ12 is overexpressed in tissues of gastric carcinoma, SUZ12 is an independent prognosis factor of patients with gastric carcinoma.